Hyperhomocysteinemia and cardiovascular diseases.
Guieu R, Ruf J, Mottola G.
Ann Biol Clin (Paris). 2022 Feb 1;80(1):7-14. doi: 10.1684/abc.2021.1694.
Hyperhomocysteinemia in Cardiovascular Diseases: Revisiting Observational Studies and Clinical Trials.
Guéant JL, Guéant-Rodriguez RM, Oussalah A, Zuily S, Rosenberg I.
Thromb Haemost. 2023 Mar;123(3):270-282. doi: 10.1055/a-1952-1946. Epub 2022 Sep 28.
Hyperhomocysteinemia is an emerging comorbidity in ischemic stroke.
Poddar R.
Exp Neurol. 2021 Feb;336:113541. doi: 10.1016/j.expneurol.2020.113541. Epub 2020 Dec 3.
Hyperhomocysteinemia and cardiovascular disease in animal model.
Azad MAK, Huang P, Liu G, Ren W, Teklebrh T, Yan W, Zhou X, Yin Y.
Amino Acids. 2018 Jan;50(1):3-9. doi: 10.1007/s00726-017-2503-5. Epub 2017 Oct 10.
Hyperhomocysteinemia and thrombosis.
Cattaneo M.
Lipids. 2001;36 Suppl:S13-26. doi: 10.1007/s11745-001-0677-9.
Hyperhomocysteinemia: Impact on Neurodegenerative Diseases.
Sharma M, Tiwari M, Tiwari RK.
Basic Clin Pharmacol Toxicol. 2015 Nov;117(5):287-96. doi: 10.1111/bcpt.12424. Epub 2015 Jun 19.
Hyperhomocysteinemia: Focus on Endothelial Damage as a Cause of Erectile Dysfunction.
Salvio G, Ciarloni A, Cutini M, Balercia G.
Int J Mol Sci. 2021 Jan 3;22(1):418. doi: 10.3390/ijms22010418.
Causes of hyperhomocysteinemia and its pathological significance.
Kim J, Kim H, Roh H, Kwon Y.
Arch Pharm Res. 2018 Apr;41(4):372-383. doi: 10.1007/s12272-018-1016-4. Epub 2018 Mar 19.
Hyperhomocysteinemia and immune activation.
Schroecksnadel K, Frick B, Winkler C, Leblhuber F, Wirleitner B, Fuchs D.
Clin Chem Lab Med. 2003 Nov;41(11):1438-43. doi: 10.1515/CCLM.2003.221.
Parkinson's Disease Risk and Hyperhomocysteinemia: The Possible Link.
Al-Kuraishy HM, Al-Gareeb AI, Elewa YHA, Zahran MH, Alexiou A, Papadakis M, Batiha GE.
Cell Mol Neurobiol. 2023 Aug;43(6):2743-2759. doi: 10.1007/s10571-023-01350-8. Epub 2023 Apr 19.
